News | April 29, 2023
TPAG organizes Thalassemia & SCD prevention discussion
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
Science communication brings behavioural changes
To enable company to be future-ready by tapping potential in CDMO space
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
Bourgoin early development hub broadens offerings for oral solid dose formulations
Subscribe To Our Newsletter & Stay Updated
